

Reportable Diseases/Conditions in Tennessee Laboratory List

(Healthcare Provider Requirements Differ)

Did you know that you are required to report certain disease and conditions to the Tennessee Department of Health?

You are an invaluable part of disease reporting and surveillance in Tennessee!

These lab reporting requirements apply to all labs located within TN as well as those that test residents of TN, including labs located within healthcare facilities.


Please report disease or conditions listed here to your local health office (listed at www.tn.gov/health/health-program-areas/localdepartments.html) or the state office via fax.at 615-741-3857.

You may also report <u>online</u> via NBS. To request an NBS account for reporting, please fill out the user survey at https://redcap.health.tn.gov/redcap/surveys/?s=8L7CMWHN4M.

To discuss reporting your lab results <u>electronically</u>, please visit <u>https://www.tn.gov/health/cedep/meaningful-use-summary/laboratory-result-reporting.html</u> to review TDH's ELR specifications and then email <u>ceds.informatics@tn.gov</u>.

Regular Reporting

PH-1600 only in 1 week (all diseases)



Phone next business day + PH-1600 in 1 week

Special Reporting



All blood lead test results must be reported electronically or via fax. For more information, refer to www.tn.gov/health/health-program-areas/mch-lead/for-providers.html or email UT Extension at leadtrk@utk.edu for assistance.





Refer to online reporting requirements for COVID-19 www.tn.gov/health/cedep/ncov/healthcare-providers.html.

Specimen or Isolate Submission



Required Requested

Outbreaks and Events of Urgent Public Health Concern:

Disease clusters or outbreaks!

Asimatahaatan arasina. Carlanaanan Dasiata

 Single cases of pan-nonsusceptible organisms, unusual resistance mechanisms, or other emerging or unusual pathogen*!

*See Appendix A of the M100 Performance Standards for Antimicrobial Susceptibility Testing

| Acinetobacter species: Carbapenem-Resistant | еір | 4 |
|---|----------|---|
| Anaplasma phagocytophilum , species | | |
| Babesia species | | |
| Bacillus anthracis | ! | Δ |
| Bordetella pertussis | 2 | |
| Borrelia burgdorferi | | |
| Brucella species | 2 | Ā |
| Burkholderia mallei | ! | A |
| pseudomallei | ! | A |
| California/LaCrosse serogroup viruses | | |
| Campylobacter species | <u>A</u> | |
| Candida auris (includes rule-out) | 2 | Ā |
| Chikungunya virus | 2 | |
| Chlamydia trachomatis | | |
| Clostridium botulinum or botulinum toxin: | | |
| Foodborne | ! | Δ |
| Wound | ! | A |
| Infant | Δ | |
| Clostridium difficile | eip | İ |
| Clostridium tetani | | |
| Coronavirus disease (COVID-19) caused by SARS—CoV-2 (+/-) | *** | |
| Corynebacterium diphtheria | 2 | Ϫ |
| ulcerans | | Ϫ |
| Coxiella burnetii | 2 | Ā |
| Cryptosporidium species | A | |

| Cyclospora species | <u> </u> |
|---|------------|
| Dengue virus | |
| Ehrlichia species | |
| Enterobacterales: Carbapenem-Resistant (any organism from the Enterobacterales order including but not limited to Escherichia coli, Enterobacter sp, and Klebsiella sp) | Δ |
| Enterococcus species: Vancomycin-Resistant Invasive Disease | |
| Escherichia coli: Extended Spectrum Beta Lactamase-Producing | eip 🛭 |
| Escherichia coli: Shiga toxin-producing | Δ |
| Equine Encephalitis viruses: | |
| Eastern | |
| Venezuelan | |
| Western | |
| Francisella tularensis | ☎ △ |
| Haemophilus influenzae | 2 4 |
| Hepatitis A virus | 2 |
| Hepatitis B virus | |
| Hepatitis C virus | |
| Human Immunodeficiency Virus (including pregnancy-associated) | |
| Influenza A virus: Novel | ! ▲ |
| Klebsiella species: Extended Spectrum Beta Lactamase-Producing | eip 🗓 |
| Beta Lactamase-Producing | Lip |
| Lead Levels | Extension |
| Legionella species | <u>A</u> |
| Listeria species | Δ. |
| Measles virus | . A |



Reportable Diseases/Conditions in Tennessee Laboratory List

(Healthcare Provider Requirements Differ)

Outbreaks and Events of Urgent Public Health Concern:

- Disease clusters or outbreaks!
- Single cases of pan-nonsusceptible organisms, unusual resistance mechanisms, or other emerging or unusual pathogen*!

*See Appendix A of the M100 Performance Standards for Antimicrobial Susceptibility Testing

| Meningitis: Other Bacterial | 2 A |
|---|------------|
| Middle East Respiratory Syndrome Coronavirus (MERS-CoV) | ! ▲ |
| Mumps virus | * |
| Mycobacterium leprae | <u> </u> |
| Mycobacterium nontuberculous species (extra-pulmonary only) | |
| Mycobacterium tuberculosis complex | |
| M. tuberculosis | 2 A |
| M. bovis | 2 A |
| M. canettii | 2 A |
| M. africanum | 2 A |
| M. microti | 2 A |
| Neisseria gonorrhoeae | |
| Neisseria meningitidis | ! <u>A</u> |
| Plasmodium species | <u>A</u> |
| Poliovirus | ! 4 |
| Rabies virus: | |
| Animal | |
| Human | ! <u>A</u> |
| Ricin toxin | ! ▲ |
| Rickettsia species (other than R. typhus) | |
| Rubella virus | 2 A |
| St. Louis Encephalitis virus | |
| Salmonella: | |
| Typhi | 2 A |
| Other species | <u> </u> |
| • | |

| The state of the s | |
|--|------------|
| Shigella species | Δ |
| Staphylococcus aureus: | |
| Enterotoxin B-producing (pulmonary) | ! ▲ |
| Methicillin-Resistant Invasive Disease | eip |
| Toxin-producing (TSST-1) | |
| Vancomycin Non-Susceptible (All Forms) | 2 A |
| Streptococcus agalactiae Invasive Disease | |
| Streptococcus pneumoniae Invasive Disease | Δ |
| Streptococcus pyogenes: | Δ |
| Invasive Disease | A A |
| Toxin-producing | <u> </u> |
| Treponema pallidum: | |
| Congenital | * |
| Other | |
| Frypanosoma cruzi | |
| Variola virus (Orthopox virus) | ! ▲ |
| Vibrio: | |
| Cholerae | Δ |
| Species | Δ |
| Viral Hemorrhagic Fever viruses (including Ebola, Lassa, Marburg) | ! |
| West Nile virus | |
| Yellow Fever virus | 2 A |
| Yersinia: pestis | |
| Pestis | 2 A |
| Species | |
| Zika virus | 2 |

Electronic Laboratory Reporting Details (cont.)

The on-boarding process to exchange ELR data with the Tennessee Department of Health (TDH) requires registration by each potential trading partner in the TDH <u>Trading Partner</u> Registration (TPR) system.

The TPR provides documentation that can be utilized for Meaningful Use (MU) attestation, and allows users to view their progress from end to end through the use of milestone letters documenting the on-boarding process. If you have not yet registered with TDH in the TPR system and you wish to send ELR to TDH, please contact MU.Health@tn.gov for assistance.

For more information on ELR on-boarding, including the on-boarding process, on-boarding checklist, frequently asked questions, business rules, and message format and vocabulary, please see the <u>ELR On-Boarding Packet</u>.

Regular Reporting

PH-1600 only in 1 week (all diseases)

Phone immediately + PH-1600 in 1 week

Phone next business day + PH-1600 in 1 week

Special Reporting



All blood lead test results must be reported electronically or via fax. For more information, refer to www.tn.gov/health/health-program-areas/mch-lead/for-providers.html or email UT Extension at leadtrk@utk.edu for assistance.

Refer to the Detailed Laboratory Guidance for catchment area and/or send questions to HAI.Health@tn.gov.



Refer to online reporting requirements for COVID-19 www.tn.gov/health/cedep/ncov/healthcare-providers.html.

Specimen or Isolate Submission



Required

Requested

More information about reporting is available on the Reportable Diseases website at www.tn.gov/health/cedep/reportable diseases.html. For questions, contact CEDEP at (615) 741-7247 or (800) 404-3006. For more details about the laboratory tests and results, specimen or isolate submission requirements, and catchment areas for individual pathogens, please refer to the 2021 Reportable Diseases in Tennessee: Detailed